Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 89 for:    DESVENLAFAXINE

A Study of LY03005 vs Pristiq

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03733574
Recruitment Status : Completed
First Posted : November 7, 2018
Last Update Posted : November 9, 2018
Sponsor:
Information provided by (Responsible Party):
Luye Pharma Group Ltd.

Brief Summary:
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: LY03005 Drug: Pristiq Phase 1

Detailed Description:
Fifty six (56) eligible subjects will be enrolled and assigned to either Group A or Group B at a 1:1 ratio.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, 2-Treatment, 2-Sequence, 2-Period Crossover Trial to Assess the Bioequivalence of 80 mg LY03005 to 50 mg Pristiq After Single Dose Administration Under Fasting Conditions to Healthy Subjects
Actual Study Start Date : June 19, 2018
Actual Primary Completion Date : July 17, 2018
Actual Study Completion Date : July 26, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LY03005 cross-over to Pristiq® (Desvenlafaxine)
Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
Drug: LY03005
Drug: LY03005 80 mg, oral tablets, single dose

Drug: Pristiq
Drug: Pristiq 50 mg, oral tablets, single dose
Other Name: Desvenlafaxine

Experimental: Pristiq® (Desvenlafaxine) cross-over to LY03005
Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
Drug: LY03005
Drug: LY03005 80 mg, oral tablets, single dose

Drug: Pristiq
Drug: Pristiq 50 mg, oral tablets, single dose
Other Name: Desvenlafaxine




Primary Outcome Measures :
  1. concentration-time curve (AUC) [ Time Frame: 15 days ]
    Plasma ODV area under the concentration-time curve (AUC)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Capable of giving informed consent and complying with trial procedures;
  2. Male and female subjects between the ages of 18 and 50 years, inclusive;
  3. Considered healthy by the Investigator based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;
  4. Nonsmoker, defined as not having smoked or used any form of tobacco for at least 6 months before Screening based on subject report;
  5. Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg;
  6. Willing and able to adhere to trial procedures and to be confined at the clinical research unit (CRU).
  7. All female subjects (childbearing potential and non-childbearing potential) must have a negative serum pregnancy test result at Screening. In addition, female subjects must meet 1 of the following 3 conditions: (i) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) based on subject report, or (iii) if of childbearing potential and heterosexually active, practicing or agree to practice a highly effective method of contraception. Highly effective methods of birth control include an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable birth control method if the vasectomized partner is the sole sexual partner of the female subject and the vasectomized partner has received medical confirmation of surgical success.

Highly effective methods of birth control must be used for at least 14 days prior to study drug dosing, through the end of study (EOS) visit or early termination, and for a minimum of 1 month after the last dose of study drug to minimize the risk of pregnancy. Sexually active, fertile, male subjects must be willing to use acceptable contraception methods (such as double-barrier methods of a combination of male condom with either cap, diaphragm, or sponge with spermicide) from the first dose of study drug through the EOS visit or early termination, and for a minimum of 1 month after the last dose of study drug.

Exclusion Criteria:

  1. Clinically significant past medical history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric (including life-long history of depression and/or anxiety), renal, hepatic, bronchopulmonary, neurologic, immunologic, ophthalmological, or lipid metabolism disorders; or drug hypersensitivity; or any other condition that in the judgement of the Investigator will affect the trial results or the subject's safety;
  2. History of suicide attempt in the past 12 months and/or seen by the Investigator as having a significant history of risk of suicide or homicide;
  3. History or presence of malignancy other than adequately treated and cured basal cell carcinoma or squamous cell carcinoma (skin cancer);
  4. Clinically relevant illness within 1 month prior to Screening or at Screening that may interfere with the conduct of this trial;
  5. Medically uncontrolled high blood pressure with mean systolic blood pressure >140 mmHg or mean diastolic blood pressure >90 mmHg at Screening after 3 measurements (after at least 5 minutes of rest in a seated position);
  6. History of Long QT Syndrome (LQTS) or a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);
  7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
  8. History of seizure (history of febrile seizure allowed);
  9. Hospital admission or major surgery within 30 days prior to Screening;
  10. Participation in any other investigational drug trial within 30 days prior to Screening;
  11. History of prescription drug abuse or illicit drug use within 6 months prior to Screening;
  12. History of alcohol abuse according to medical history within 6 months prior to Screening;
  13. Positive screen for alcohol and/or drugs of abuse;
  14. Tobacco use within 6 months prior to Screening based on positive nicotine screen;
  15. History of intolerance or hypersensitivity to ODV or medicines containing ODV or its precursor venlafaxine;
  16. Participation in a previous clinical trial of either LY03005 or ODV or medicines containing ODV or its precursor, venlafaxine, within 30 days prior to Screening;
  17. Unwillingness or inability to comply with food and beverage restrictions during trial participation;
  18. Donation of blood of more than 1 unit (approximate 450 mL) or blood products or acute loss of blood during the 90 days prior to Screening;
  19. Use of prescription or over-the-counter (OTC) medications and/or herbals (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at <3g/day is permitted until 24 hours prior to dosing).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03733574


Locations
Layout table for location information
United States, Maryland
Pharmaron CPC, Inc.
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Luye Pharma Group Ltd.
Investigators
Layout table for investigator information
Study Chair: Amy Sun, MD, PhD, MBA Luye Pharma Group Ltd.

Additional Information:
Layout table for additonal information
Responsible Party: Luye Pharma Group Ltd.
ClinicalTrials.gov Identifier: NCT03733574     History of Changes
Other Study ID Numbers: LY03005/CT-USA-106
First Posted: November 7, 2018    Key Record Dates
Last Update Posted: November 9, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Luye Pharma Group Ltd.:
Desvenlafaxine Succinate
Depressive Disorder, Major
Depressive Disorder
Mood Disorders
Mental Disorders
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents
Psychotropic Drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Desvenlafaxine Succinate
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Neurotransmitter Agents
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antidepressive Agents
Psychotropic Drugs